Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: A meta-analysis

Nephrology

Volumn 18, Issue 2, 2013, Pages 104-110

  Feng, Li ^a   Deng, Jin ^b   Huo, Dong Mei ^a   Wu, Qiao Yuan ^a   Liao, Yun Hua ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

azathioprine; lupus nephritis; meta analysis; mycophenolate mofetil

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

AMENORRHEA; ARTICLE; COCHRANE LIBRARY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; EMBASE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MEDLINE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SYSTEMATIC REVIEW;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; CHILD; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872719028     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12006     Document Type: Article

References (32)

1. Mok CC,. Understanding lupus nephritis: Diagnosis, management, and treatment options. Int J Womens Health 2012; 4: 213-222.
2. Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC,. Renal damage in systemic lupus erythematosus: A comparative analysis of different age groups. Lupus 2007; 16: 28-34.
3. Mills JA,. Systemic lupus erythematosus. N. Engl. J. Med. 1994; 330: 1871-1879.
4. Ward MM, Pyun E, Studenski S,. Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus. Arch. Intern. Med. 1996; 156: 1337-1344.
5. Waldman M, Appel GB,. Update on the treatment of lupus nephritis. Kidney Int. 2006; 70: 1403-1412.
6. Mok CC, Wong RW, Lai KN,. Treatment of severe proliferative lupus nephritis: The current state. Ann. Rheum. Dis. 2003; 62: 799-804.
7. Ponticelli C, Moroni G,. Flares in lupus nephritis: Incidence, impact on renal survival and management. Lupus 1998; 7: 635-638.
8. Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus 2009; 18: 257-263.
9. Boumpas DT, Austin HA, 3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340: 741-745.
10. Gourley MF, Austin HA, 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med. 1996; 125: 549-557.
11. Ponticelli C, Glassock RJ, Moroni G,. Induction and maintenance therapy in proliferative lupus nephritis. J. Nephrol. 2010; 23: 9-16.
12. Allison AC, Eugui EM,. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
13. Allison AC,. Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14 (Suppl 1): s2-8.
14. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 2004; 350: 971-980.
15. Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 2011; 365: 1886-1895.
16. Tesar V, Hruskova Z,. Treatment of proliferative lupus nephritis: A slowly changing landscape. Nat Rev Nephrol 2011; 7: 96-109.
17. Sahin GM, Sahin S, Kiziltas S, Masatlioglu S, Oguz F, Ergin H,. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis. Ren. Fail. 2008; 30: 865-869.
18. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis. 2010; 69: 2083-2089.
19. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control. Clin. Trials 1996; 17: 1-12.
20. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-613.
21. Kjaergard LL, Villumsen J, Gluud C,. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann. Intern. Med. 2001; 135: 982-989.
22. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002; 21: 1539-1558.
23. Chan TM, Tse KC, Tang CS, Mok MY, Li FK,. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 2005; 16: 1076-1084.
24. Sinclair A, Appel G, Dooley MA, et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: Rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 2007; 16: 972-980.
25. Zhu B, Chen N, Lin Y, et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: A meta-analysis of randomized controlled trials. Nephrol. Dial. Transplant. 2007; 22: 1933-1942.
26. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG,. Induction and maintenance therapy for lupus nephritis: A systematic review and meta-analysis. Lupus 2010; 19: 703-710.
27. Vento M, Perez Aytes A, Ledo A, Boso V, Carey JC,. Mycophenolate mofetil during pregnancy: Some words of caution. Pediatrics 2008; 122: 184-185.
28. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA,. Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature. Am. J. Med. Genet. A 2009; 149A: 1241-1248.
29. Sterne JA, Gavaghan D, Egger M,. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J. Clin. Epidemiol. 2000; 53: 1119-1129.
30. Pablos JL, Gutierrez-Millet V, Gomez-Reino JJ,. Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal. Scand. J. Rheumatol. 1994; 23: 142-144.
31. Mosca M, Neri R, Giannessi S, et al. Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis. Lupus 2001; 10: 253-257.
32. Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: Long-term follow-up. Nephrol. Dial. Transplant. 2006; 21: 1541-1548.